Angiochem Announces Presentations at Six Upcoming Conferences

MONTREAL--(BUSINESS WIRE)--Angiochem, a clinical stage biotechnology company, today announced presentations at six upcoming biotechnology conferences:

“A new brain-penetrant Angiopep-2-morphine-6-glucuronide derivative (ANG2010) with analgesic properties”

• Boulder Peptide symposium, September 26-28, 2012, Boulder, CO
  • Jean E. Lachowicz Ph.D., Chief Scientific Officer of Angiochem will provide an oral presentation entitled “Peptide Drug Conjugates Designed To Cross The Blood-Brain Barrier” in a session discussing the use of novel technologies to enhance peptide therapeutics
• BioContact Conference, October 3-4, 2012, Quebec City
  • Jean Paul Castaigne, MD, President and CEO of Angiochem will provide a company update
• Society for Neuroscience, October 13-17, 2012, New Orleans, LA
  • Michel Demeule Ph.D., Director of Research will present a poster (#173.26/AA7) entitled “A new brain-penetrant Angiopep-2-morphine-6-glucuronide derivative (ANG2010) with analgesic properties” in a session related to Ligands, Receptors and Therapy
  • Jean E. Lachowicz, Ph.D., Chief Scientific Officer of Angiochem will present a poster (#173.28/AA9 ) entitled “Analgesic properties of a novel brain-penetrant Angiopep-2-neurotensin derivative (ANG2002) for treating chronic pain” in a session related to Ligands, Receptors and Therapy
• BioNetwork West, October 15-17, 2012, Laguna Niguel, CA
  • Pamela Esposito, Senior Vice President of Strategic Planning and Business Development of Angiochem will participate in a panel discussing Trends In Life Sciences M&A Activity.
• Bio-Europe 2012, November 12-14, 2012, Hamburg, Germany
  • Jean Paul Castaigne, MD, President and CEO of Angiochem will provide a company update
• Society for Neuro-Oncology 17^th Annual Scientific Meeting, November 15-18, 2012, Washington, DC
  • Jean Lachowicz Ph.D., Chief Scientific Officer of Angiochem will present a poster (#528) entitled “Design of new Angiopep-2-anti-EGFR and Angiopep-2-anti-Her2 derivatives with increased blood-brain barrier permeability for treatment of brain tumors.”

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new EPiC compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and lysosomal storage diseases, pain, and others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.